Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

Extended collaboration will further explore the capabilities of Medidata Platform from early-phase trials to post-marketing ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, looks back to 2024 and discusses some of the industry’s ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights increased data management, DE&I, and ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights how artificial intelligence, real-time ...

The Phase III INAVO120 trial found that a combination of Itovebi (inavolisib) with Ibrance (palbociclib) and Faslodex (fulvestrant) significantly improved overall survival and progression-free ...

End-to-end offering is designed to streamline site activation and optimize visibility in critical research processes.

Use of decentralized approach in a Phase 1 pharmacokinetic trial shows the ability to enable remote data collection and ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, discusses challenges such as high costs and long ...

Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...

“The goal is to develop life-saving medications for patients faster. That comes down to saving time and money,” said Bonne ...

Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia ...